https://www.live-feeds.com/feed/moderna-and-merck-say-their-mrna-cancer-vaccine-cut-death-recurrence-by-42Continuously updated, source-cited coverage. https://www.live-feeds.com/feed/moderna-and-merck-say-their-mrna-cancer-vaccine-cut-death-recurrence-by-42https://www.live-feeds.com/feed/moderna-and-merck-say-their-mrna-cancer-vaccine-cut-death-recurrence-by-42#u160818Thu, 29 Oct 2026 04:35:33 +0000Moderna and Merck's mRNA cancer vaccine, when combined with Merck's immunotherapy Keytruda, reduced the risk of melanoma death or recurrence by 42% in a late-stage trial. The vaccine is personalized and targets the deadliest form of skin cancer. This development could pave the way for a new era of personalized treatment. The trial's results met Wall Street expectations but triggered a 'sell-the-news reaction'.Why it mattersMelanoma is the deadliest form of skin cancer, and current treatments have limited success rates. Personalized mRNA vaccines have been a promising a